Sermorelin and NAD+ often appear on the same longevity menu, but they are different substances with different biological roles. Sermorelin is a peptide that stimulates growth-hormone-related signaling. NAD+ is a coenzyme involved in cellular metabolic processes. One is not a stronger or more complete version of the other.
The shared marketing language—energy, recovery, healthy aging—can make them seem directly comparable. A useful comparison begins with the exact problem you want to address, the route proposed, and the evidence for that product. Neither belongs in a treatment plan simply because it appears in a longevity bundle.
Sermorelin and NAD+ are not interchangeable treatments. A role in normal biology does not establish that taking either improves longevity or energy.
Separate the substance from the delivery method
NAD-related products include intravenous infusions, injections, oral products, and products containing precursors rather than NAD+ itself. Those are not interchangeable evidence categories. A study of an oral precursor does not demonstrate the clinical benefit or safety of an NAD+ infusion.
Sermorelin also has route-specific questions, including injections, dissolvable tablets, and nasal preparations. Our evidence guide explains why a study needs to match the actual intervention before supporting a claim.
What does a biological role establish?
A substance's importance inside the body does not prove that giving more of it improves a health outcome. Treatment must reach the relevant tissues in an appropriate form and produce a meaningful benefit with acceptable risks. Those questions require human evidence.
The Endocrine Society's statement on hormones and aging provides context for sermorelin-related hormone claims. It does not validate an NAD+ program. Likewise, a biochemical explanation of NAD+ is not a clinical trial showing that an infusion reverses aging or reliably treats fatigue.
Injectable NAD+ has specific quality concerns
The FDA has warned about ingredients used in sterile NAD+ compounding, including the use of food-grade material without appropriate processing. It has received reports of reactions such as severe chills, shaking, vomiting, and fatigue after injectable NAD+ products, with some requiring medical treatment.
Those reports concern product quality and safety. They are not evidence that every product causes the same reaction, but they undermine claims that an injectable preparation is automatically safe because NAD+ occurs naturally in the body.
For any sterile compounded medicine, ask which pharmacy prepares it, how the supply is handled, and who responds to a reaction. The FDA's compounding overview explains the difference between compounding and FDA product approval.
Can sermorelin and NAD+ be used together?
Olympia's catalog lists an injectable NAD+ and sermorelin bundle. A marketed bundle establishes availability in a catalog, not a controlled demonstration that combined use improves outcomes. Separate packaged products also do not imply permission to mix them in one syringe.
Our stacking guide explains why combining agents makes the evidence and monitoring questions more complicated. Ask what each is meant to accomplish, what supports using them together, and how the clinician would identify the cause of an adverse effect.
Compare the full practical commitment
An infusion visit, a home injection program, and an oral product have different time, equipment, and follow-up needs. Ask for the total treatment cost, the number of visits or supplies included, and whether laboratory work and follow-up are separate charges.
Avoid comparing a one-time infusion price with an advertised monthly peptide rate as though both represent the same care. Price should be considered after the formulation and treatment goal are clear.
What if your main concern is fatigue?
Persistent or new fatigue deserves an assessment that considers sleep, other medicines, medical conditions, and daily demands. A product sold for energy should not replace that evaluation. Ask which possible causes are being investigated and what findings would support a specific intervention.
The alternatives guide organizes treatment questions around the underlying goal. A worthwhile plan explains the expected benefit, remaining uncertainty, and reassessment point, including the option that neither of these products is needed.
Sources & further reading
Provider pages describe offers; they do not independently establish treatment benefits. Sources checked September 20, 2026.
This article is education, not a diagnosis, prescription, or dosing plan. Discuss treatment and alternatives with a licensed clinician who knows your history. Compounded medications are not FDA-approved.